Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

NASDAQ:LGND   4:00:00 PM EDT
71.65
-1.96 (-2.66%)
4:04:10 PM EDT: $70.89 -0.76 (-1.06%)
Other Pre-Announcement

Ligand Pharmaceuticals Inc Expects FY22 Total Revenue Between $184 Mln To $189 Mln

Published: 11/07/2022 21:35 GMT
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) - Ligand Reports Third Quarter 2022 Financial Results.
Expect FY22 Total Revenue of $184 Million to $189 Million.
Revenue for the Third Quarter of 2022 Was $66.1 Million, Compared With $64.8 Million for the Same Period in 2021.
Diluted Net Income per Share $0.02.
Q3 Earnings per Share View $0.43, Revenue View $38.3 Million -- Refinitiv Ibes Data (analyst estimates).